Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

Cited by (1,004)

Items 101–200 of 1,004

1. At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy
   Neil Vasan, Lewis C. Cantley · 2022 · Nature Reviews Clinical Oncology
2. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial
   Susan Faye Dent, Javier Cortés, Young‐Hyuck Im, Veronique C Dieras, Nadia Harbeck, Ian E. Krop, Timothy Richard Wilson, N. Cui, Frauke Schimmöller, Jerry Y. Hsu et al. · 2020 · Annals of Oncology
3. FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer
   Xiaoyong Fu, Resel Pereira, Carmine De Angelis, Jamunarani Veeraraghavan, Sarmistha Nanda, Lanfang Qin, Maria Letizia Cataldo, Vidyalakshmi Sethunath, Sepideh Mehravaran, Carolina Gutiérrez et al. · 2019 · Proceedings of the National Academy of Sciences
4. Overview of the relevance of PI3K pathway in HR-positive breast cancer
   N. Vasan, Eneda Toska, Maurizio Scaltriti · 2019 · Annals of Oncology
5. Beyond PI3Ks: targeting phosphoinositide kinases in disease
   Burke, John E., Triscott, Joanna, Emerling, Brooke M., Hammond, Gerald R. V. · 2023 · Nature Reviews Drug Discovery
6. Role of protein phosphorylation in cell signaling, disease, and the intervention therapy
   Kun Pang, Wei Wang, Jiaxin Qin, Zhenduo Shi, Lin Hao, Yuyang Ma, Hao Xu, Zhuo‐Xun Wu, Deng Pan, Zhe‐Sheng Chen et al. · 2022 · MedComm
7. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
   Pedram Razavi, Maura N. Dickler, Payal Deepak Shah, Weiyi Toy, David N. Brown, Helen H. Won, Bob T. Li, Ronglai Shen, Neil Vasan, Shanu Modi et al. · 2020 · Nature Cancer
8. TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer
   Brian David Lehmann, Vandana Gupta Abramson, Melinda E. Sanders, Erica L. Mayer, Tufia C. Haddad, Rita Nanda, Catherine H. Van Poznak, Anna Maria Storniolo, Julie R. Nangia, Paula I. González Ericsson et al. · 2019 · Clinical Cancer Research
9. Developing dietary interventions as therapy for cancer
   Samuel R. Taylor, John N. Falcone, Lewis C. Cantley, Marcus DaSilva Goncalves · 2022 · Nature reviews. Cancer
10. Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies
    Özge Saatci, Kim‐Tuyen Huynh‐Dam, Özgür Şahin · 2021 · Journal of Molecular Medicine
11. Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study
    Martin H. Dreyling, Armando Santoro, Luigina R. Mollica, Sirpa Leppä, George Follows, Georg Lenz, Won Seog Kim, Arnon Nagler, Maria Dimou, Judit Demeter et al. · 2019 · American Journal of Hematology
12. Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs
    Bishal Gyawali, Spencer Phillips Hey, Aaron Seth Kesselheim · 2020 · EClinicalMedicine
13. Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
    Jin Sun Lee, Susan Elaine Yost, Yuan Yuan · 2020 · Cancers
14. Mast Cells: A New Frontier for Cancer Immunotherapy
    Jake N. Lichterman, Sangeetha Meda Reddy · 2021 · Cells
15. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial
    Kevin M. Kalinsky, Jennifer Robinson Diamond, Linda T. Vahdat, Sara M. Tolaney, Dejan Juric, Joyce O’Shaughnessy, R.L. Moroose, Ingrid A. Mayer, Vandana Gupta Abramson, David M. Goldenberg et al. · 2020 · Annals of Oncology
16. Regulation of breast cancer metastasis signaling by miRNAs
    Belinda J. Petri, Carolyn M. Klinge · 2020 · Cancer and Metastasis Reviews
17. Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications: A Scientific Statement From the American Heart Association
    Tochi M. Okwuosa, Alicia Katherine Morgans, June‐Wha Rhee, Kerryn W. Reding, Sally L. Maliski, Juan-Carlos Plana, Annabelle Santos Volgman, Kendall F. Moseley, Charles Porter, Roohi R. Ismail-Khan · 2021 · Circulation Genomic and Precision Medicine
18. Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update
    Norah Lynn Henry, Mark R. Somerfield, Zoneddy Ruiz Dayao, ANTHONY D. ELIAS, Kevin M. Kalinsky, Lisa M. McShane, Beverly Moy, Ben Ho Park, Kelly M. Shanahan, Priyanka Sharma et al. · 2022 · Journal of Clinical Oncology
19. Targeted therapy for breast cancer: An overview of drug classes and outcomes
    Aaron T. Jacobs, Diana Martinez Castaneda-Cruz, Mark M. Rose, Linda Connelly · 2022 · Biochemical Pharmacology
20. Senescence as a therapeutically relevant response to CDK4/6 inhibitors
    Wagner, Verena, Gil, Jesús · 2020 · Oncogene
21. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial
    Sacha Jon Howell, Angela Claire Casbard, Margherita Carucci, Kate Ingarfield, Rachel Butler, Siân Morgan, Magdalena Meissner, Catherine Jane Bale, Pavel Bezecny, Sarah Moon et al. · 2022 · The Lancet Oncology
22. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer
    Neil A. O’Brien, Martina S.J. McDermott, Dylan F. Conklin, Tong Luo, Raul Ayala, Suruchi Salgar, Kevin Chau, Emmanuelle DiTomaso, Naveen Babbar, Faye Su et al. · 2020 · Breast Cancer Research
23. Breast cancer in the era of precision medicine
    Negar Sarhangi, Shahrzad Hajjari, Seyede Fatemeh Heydari, Maryam Ganjizadeh, Fatemeh Rouhollah, Mandana Hasanzad · 2022 · Molecular Biology Reports
24. Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer
    Karen Van Baelen, Tatjana Geukens, Marion Maetens, Vivianne C. G. Tjan‐Heijnen, Christopher J. Lord, SC Linn, François‐Clément Bidard, François Richard, William W. Yang, Rebecca E. Steele et al. · 2022 · Annals of Oncology
25. Targeting PI3K/AKT/mTOR Signaling Pathway in Pancreatic Cancer: From Molecular to Clinical Aspects
    Silviu Stanciu, Florentina Ioniţă Radu, Constantin Ștefani, Daniela Miricescu, Iulia-Ioana Stănescu-Spînu, Maria Greabu, Alexandra Totan, Mariana Jinga · 2022 · International Journal of Molecular Sciences
26. Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
    Giuseppe Lamberti, Elisa Andrini, Monia Sisi, Alessandro Rizzo, Claudia Parisi, Alessandro Di Federico, Francesco Gelsomino, Andrea Ardizzoni · 2020 · Critical Reviews in Oncology/Hematology
27. Management of toxicity to isoform α-specific PI3K inhibitors
    Nunnery, S.E., Mayer, I.A. · 2019 · Annals of Oncology
28. Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)
    Christian Diego Rolfo, Andrés Felipe Cardona, Massimo Cristofanilli, Luis G Paz-Ares, Juan J. Díaz‐Mochon, Ignacio Durán, Luis Estuardo Raez, Alessandro Russo, Jose Antonio Lorente, Umberto Malapelle et al. · 2020 · Critical Reviews in Oncology/Hematology
29. Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status
    Guochun Zhang, Chongyang Ren, Cheukfai Li, Yulei Wang, Bo Chen, Lingzhu Wen, Minghan Jia, Kai Li, Hsiaopei Mok, Li Cao et al. · 2022 · BMC Medicine
30. Harmonizing Cell-Free DNA Collection and Processing Practices through Evidence-Based Guidance
    Greytak, Sarah R., Engel, Kelly B., Parpart-Li, Sonya, Murtaza, Muhammed, Bronkhorst, Abel J., Pertile, Mark D., Moore, Helen M. · 2020 · Clinical Cancer Research
31. CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review)
    Jinyao Huang, Liang Zheng, Zicheng Sun, Jie Li · 2022 · International Journal of Molecular Medicine
32. Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment
    Nida Pasha, Nicholas C. Turner · 2021 · Nature Cancer
33. Acquired resistance in cancer: towards targeted therapeutic strategies
    Alice Soragni, Erik S. Knudsen, Thomas N. O’Connor, Cristina E. Tognon, Jeffrey W Tyner, Beatrice Gini, Donghwa Kim, Trever Grant Bivona, Xingxing Zang, Agnieszka Katarzyna Witkiewicz et al. · 2025 · Nature reviews. Cancer
34. Drug ranking using machine learning systematically predicts the efficacy of anti-cancer drugs
    Henry Gerdes, Pedro Casado, Arran David Dokal, Maruan Hijazi, Nosheen Akhtar, Ruth Osuntola, Vinothini Rajeeve, Jude Fitzgibbon, Jon Travers, D. Britton et al. · 2021 · Nature Communications
35. Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA
    Smita S. Chandran, Jiaqi Ma, Martin G. Klatt, Friederike Dündar, Chaitanya Bandlamudi, Pedram Razavi, Hannah Yong Wen, Britta Weigelt, Paul Zumbo, Si Ning Fu et al. · 2022 · Nature Medicine
36. The History of Early Breast Cancer Treatment
    Judith Ben-Dror, Michal Mia Shalamov, Amir Sonnenblick · 2022 · Genes
37. SGLT-2 Inhibitors in Cancer Treatment—Mechanisms of Action and Emerging New Perspectives
    Mieczysław Dutka, Rafał Bobiński, Tomasz Francuz, Wojciech Garczorz, Karolina Zimmer, Tomasz Piotr Ilczak, Michał Ćwiertnia, Maciej Błażej Hajduga · 2022 · Cancers
38. Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes
    Marcelo Sobral‐Leite, Izhar Salomon, Mark Opdam, Dinja T. Kruger, Karin J. Beelen, Vincent van der Noort, Ronald L. P. van Vlierberghe, Erik J. Blok, Daniele Giardiello, Joyce Sanders et al. · 2019 · Breast Cancer Research
39. A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours
    Mark T. J. van Bussel, Ahmad Hussein Awada, Maja J.A. de Jonge, Morten Mau‐Sørensen, Dorte Lisbet Nielsen, Patrick Schöffski, Henk M.W. Verheul, Barbara Sarholz, Karin Berghoff, Samer El Bawab et al. · 2020 · British Journal of Cancer
40. The potential of liquid biopsy in the management of cancer patients
    Athina N. Markou, Eleni Tzanikou, Evi S. Lianidou · 2022 · Seminars in Cancer Biology
41. Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives
    Stefania Cocco, Michela Piezzo, Alessandra Calabrese, Daniela Cianniello, Roberta Caputo, Vincenzo Di Lauro, Giuseppina Fusco, Germira Di Gioia, Marina Licenziato, Michelino De Laurentiis · 2020 · International Journal of Molecular Sciences
42. PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Nicola Fusco, Umberto Malapelle, Matteo Fassan, Caterina Marchiò, Simonetta Buglioni, Simona Zupo, Carmen Criscitiello, Paolo Giovanni Vigneri, Angelo Paolo Dei Tos, Eugenio Maiorano et al. · 2021 · Frontiers in Oncology
43. Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy
    Sirico, Marianna, D’Angelo, Alberto, Gianni, Caterina, Casadei, Chiara, Merloni, Filippo, De Giorgi, Ugo · 2023 · Cancers
44. Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer
    Carla L. Alves, Henrik J. Ditzel · 2023 · International Journal of Molecular Sciences
45. Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials
    Takahito Kawano, Junichi Inokuchi, Masatoshi Eto, Masaharu Murata, Jeong‐Hun Kang · 2021 · Pharmaceutics
46. Invasive lobular carcinoma: an understudied emergent subtype of breast cancer
    Jason Aboudi Mouabbi, Amy Aida Hassan, Bora Lim, Gabriel N. Hortobágyi, Debu Tripathy, Rachel M. Layman · 2022 · Breast Cancer Research and Treatment
47. Patient-derived head and neck cancer organoids allow treatment stratification and serve as a tool for biomarker validation and identification
    Rosemary Millen, W. W. B. de Kort, Mandy Koomen, Gijs J. F. van Son, Roán Gobits, Bas B. L. Penning de Vries, Harry Begthel, Maurice M.J.M. Zandvliet, Patricia Doornaert, Cornelis P.J. Raaijmakers et al. · 2023 · Med
48. Liquid Biopsy in Breast Cancer: A Focused Review
    Timothy Kwang Yong Tay, Puay Hoon Tan · 2020 · Archives of Pathology & Laboratory Medicine
49. Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer
    Lu, Yunlong, Liu, Wukun · 2020 · Journal of Medicinal Chemistry
50. Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)
    Aditya Bardia, Sara Alsterlind Hurvitz, Angela M. DeMichele, Amy Sanders Clark, Amelia Bruce Zelnak, Denise Aysel Yardley, Meghan Sri Karuturi, Tara Beth Sanft, Sibel H. Blau, Lowell L. Hart et al. · 2021 · Clinical Cancer Research
51. Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant
    Sara M. Tolaney, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Eva-Maria Grischke, Antonio Llombart‐Cussac, Hatem Soliman, Hong Wang, Sameera Wijayawardana, Valerie M. Jansen et al. · 2022 · Clinical Cancer Research
52. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
    Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Javierre Villacampa, Abel González-Pérez, Mafalda Oliveira, Fara Brasó‐Maristany, Nusaïbah Ibrahimi, Srinivasaraghavan Kannan, Leonardo Bruno Mina et al. · 2022 · Nature Communications
53. Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges
    Miguel García-Pardo, Maisam Makarem, Janice J.N. Li, Deirdre Kelly, Natasha B. Leighl · 2022 · British Journal of Cancer
54. Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role
    Maxwell Roger Lloyd, Seth Andrew Wander, Erika Paige Hamilton, Pedram Razavi, Aditya Bardia · 2022 · Therapeutic Advances in Medical Oncology
55. A P53-Phosphoinositide Signalosome Regulates Nuclear AKT Activation
    Chen, Mo, Choi, Suyong, Wen, Tianmu, Chen, Changliang, Thapa, Narendra, Lee, Jeong Hyo, Cryns, Vincent L., Anderson, Richard A. · 2022 · Nature Cell Biology
56. Cross-species oncogenic signatures of breast cancer in canine mammary tumors
    Tae‐Min Kim, In Seok Yang, Byung‐Joon Seung, Sejoon Lee, Dohyun Kim, Yoo-Jin Jiny Ha, Mi-Kyoung Seo, Ka-Kyung Kim, Hyun Seok Kim, Jae‐Ho Cheong et al. · 2020 · Nature Communications
57. Targeting Autophagy in Breast Cancer
    Stefania Cocco, Alessandra Leone, Michela Piezzo, Roberta Caputo, Vincenzo Di Lauro, Francesca Di Rella, Giuseppina Fusco, Monica Capozzi, Germira Di Gioia, Alfredo Budillon et al. · 2020 · International Journal of Molecular Sciences
58. Somatic PIK3CA Mutations in Sporadic Cerebral Cavernous Malformations
    Matthieu Peyre, Danielle F. Miyagishima, Franck Bielle, Françoise Chapon, Michael C. Sierant, Quitterie Venot, Julie Lerond, Pauline Marijon, Samiya Abi Jaoudé, Tuan Le Van et al. · 2021 · New England Journal of Medicine
59. Clinical Review on the Management of Hormone Receptor–Positive Metastatic Breast Cancer
    Nicholas Patrick McAndrew, Richard S. Finn · 2021 · JCO Oncology Practice
60. The New Era of Drug Discovery: The Power of Computer-aided Drug Design (CADD)
    Igor José dos Santos Nascimento, Thiago Mendonça de Aquino, Edeildo Ferreira da Silva‐Júnior · 2022 · Letters in Drug Design & Discovery
61. Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges
    Rohan Kalyan Rej, Junius Eugene Thomas, Ranjan Kumar Acharyya, James Michael Rae, Shaomeng Wang · 2023 · Journal of Medicinal Chemistry
62. Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity
    Sarah Christine Elisabeth Wright, Natali Vasilevski, Violeta Serra, Jordi Ahnert Rodon, Pieter J.A. Eichhorn · 2021 · Cancers
63. Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer
    Lillian Mary Smyth, Kenji Tamura, Mafalda Oliveira, Eva Ciruelos, Ingrid A. Mayer, Marie‐Paule Sablin, Laura Biganzoli, Helen J. Ambrose, Jack Ashton, Alan Barnicle et al. · 2020 · Clinical Cancer Research
64. Current Molecular Combination Therapies Used for the Treatment of Breast Cancer
    Yiling Wang, Audrey Minden · 2022 · International Journal of Molecular Sciences
65. Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer
    Pauline du Rusquec, Cyriac Blonz, Jean‐Sébastien Frenel, Mario Campone · 2020 · Therapeutic Advances in Medical Oncology
66. Single-cell resolved imaging reveals intra-tumor heterogeneity in glycolysis, transitions between metabolic states, and their regulatory mechanisms
    Kondo, Hiroshi, Ratcliffe, Colin D.H., Hooper, Steven, Ellis, James, MacRae, James I., Hennequart, Marc, Dunsby, Christopher W., Anderson, Kurt I., Sahai, Erik · 2021 · Cell Reports
67. A clinician’s handbook for using ctDNA throughout the patient journey
    Samantha Ourania Hasenleithner, Michael R. Speicher · 2022 · Molecular Cancer
68. AACR Project GENIE: 100,000 Cases and Beyond
    Trevor J. Pugh, Jonathan L. Bell, Jeffrey P. Bruce, Gary Joseph Doherty, Matthew Galvin, Michelle F. Green, Haley Hunter-Zinck, Priti Kumari, Michele L. Lenoue-Newton, Marilyn M. Li et al. · 2022 · Cancer Discovery
69. Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer
    Iseult M. Browne, Fabrice André, Sarat Chandarlapaty, LA Carey, Nicholas C. Turner · 2024 · The Lancet Oncology
70. Breast cancer liver metastasis: current and future treatment approaches
    Narmeen S Rashid, Jacqueline M. Grible, Charles V. Clevenger, Joshua Chuck Harrell · 2021 · Clinical & Experimental Metastasis
71. Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
    Andreas S. Varkaris, Ermira Pazolli, Hakan Günaydin, Qi Wang, Levi Pierce, Alessandro A. Boezio, Artemisa Bulku, Lucian DiPietro, Cary Fridrich, Adam S. Frost et al. · 2023 · Cancer Discovery
72. Current Perspectives on Circulating Tumor DNA, Precision Medicine, and Personalized Clinical Management of Cancer
    Kelly Cristina da Silva Oliveira, Iago Barroso Ramos, Jéssica Manoelli Costa da Silva, Williams Fernandes Barra, Gregory Joseph Riggins, Vikrant Palande, Catarina Torres Pinho, Milana Frenkel‐Morgenstern, Sidney Santos, Paulo Pimentel de Assumpção et al. · 2020 · Molecular Cancer Research
73. KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival.
    Yoshihisa Tokumaru, Masanori Oshi, Eriko Katsuta, Li Yan, Vikas Satyananda, Nobuhisa Matsuhashi, Manabu Futamura, Yukihiro Akao, Kazuhiro Yoshida, Kazuaki Takabe · 2020 · PubMed Central
74. Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1)
    Yoichi Naito, Hiroyuki Aburatani, Toraji Amano, Eishi Baba, Toru Furukawa, Tetsu Hayashida, Eiso Hiyama, Sadakatsu Ikeda, Masashi Kanai, Motohiro Kato et al. · 2020 · International Journal of Clinical Oncology
75. The genomic landscape of breast cancer brain metastases: a systematic review
    Alexander James Morgan, Athina Giannoudis, Carlo Palmieri · 2020 · The Lancet Oncology
76. Current Status of Circulating Tumor Cells, Circulating Tumor DNA, and Exosomes in Breast Cancer Liquid Biopsies
    Marta Tellez-Gabriel, Erik Knutsen, Maria Perander · 2020 · International Journal of Molecular Sciences
77. Nexus between PI3K/AKT and Estrogen Receptor Signaling in Breast Cancer
    Aditi Sanjay Khatpe, Adedeji Kolawole Adebayo, Christopher Herodotou, Brijesh Kumar, Harikrishna Nakshatri · 2021 · Cancers
78. Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions
    Riccardo Gerosa, Rita De Sanctis, Flavia Jacobs, C. Benvenuti, Mariangela Gaudio, Giuseppe Saltalamacchia, Rosalba Torrisi, Giovanna Masci, Chiara Miggiano, Francesco Agustoni et al. · 2024 · Critical Reviews in Oncology/Hematology
79. Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions
    Hongyao Li, Xiang Wen, Yueting Ren, Zhichao Fan, Jin Zhang, Gu He, Leilei Fu · 2024 · Molecular Cancer
80. Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives
    Dwan‐Ying Chang, Weili Ma, Yen‐Shen Lu · 2021 · Therapeutics and Clinical Risk Management
81. Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response
    Jesse Yu, Qingxin Mu, Millie Fung, Xiaolin Xu, Linxi Zhu, Rodney J. Y. Ho · 2022 · Pharmacology & Therapeutics
82. Alpelisib administration reduced lymphatic malformations in a mouse model and in patients
    F. Delestre, Quitterie Venot, Charles Bayard, Antoine Fraissenon, Sophia Ladraa, Clément Hoguin, Célia Chapelle, Junna Yamaguchi, Rubina Cassaca, Lola Zerbib et al. · 2021 · Science Translational Medicine
83. Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways
    Zhi Zhu, AJ Robert McGray, Weijian Jiang, Binfeng Lu, Paweł Kaliński, Zong Sheng Guo · 2022 · Molecular Cancer
84. Development and safety of PI3K inhibitors in cancer
    Miaomiao Yu, Jiajia Chen, Zhifei Xu, Bo Yang, Qiaojun He, Peihua Luo, Hao Yan, Xiaochun Yang · 2023 · Archives of Toxicology
85. Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial
    Kevin M. Kalinsky, Giampaolo Bianchini, Erika Paige Hamilton, Stephanie L. Graff, Kyong Hwa Park, Rinath M. Jeselsohn, Umut Demırcı, Miguel Martín, Rachel M. Layman, Sara Alsterlind Hurvitz et al. · 2024 · Journal of Clinical Oncology
86. Genomic profile of advanced breast cancer in circulating tumour DNA
    Belinda Kingston, Rosalind J. Cutts, Hannah Bye, Matthew Beaney, Giselle Walsh-Crestani, Sarah Hrebien, Claire Swift, Lucy Kilburn, Sarah Kernaghan, Laura Moretti et al. · 2021 · Nature Communications
87. VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results
    Geoffrey John Lindeman, Tharu M. Fernando, Rebecca L. Bowen, Katarzyna Joanna Jerzak, Xinni Song, Thomas W. Decker, Frances M. Boyle, Steve McCune, Anne Caroline Armstrong, Catherine Shannon et al. · 2022 · Clinical Cancer Research
88. FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022
    Carla Rizzo, Sara Amata, Ivana Pibiri, Andrea Pace, Silvestre Buscemi, Antonio Palumbo Piccionello · 2023 · International Journal of Molecular Sciences
89. Liver lipophagy ameliorates nonalcoholic steatohepatitis through extracellular lipid secretion
    Yoshito Minami, Atsushi Hoshino, Yusuke Higuchi, Masahide Hamaguchi, Yusaku Kaneko, Yuhei Kirita, Shunta Taminishi, Toshiyuki Nishiji, Akiyuki Taruno, Michiaki Fukui et al. · 2023 · Nature Communications
90. Preanalytical variables that affect the outcome of cell-free DNA measurements
    Vida Ungerer, Abel Jacobus Bronkhorst, Stefan Holdenrieder · 2020 · Critical Reviews in Clinical Laboratory Sciences
91. PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway
    Huayu Hu, Junyong Zhu, Yuting Zhong, Rui Geng, Yashuang Ji, Qingyu Guan, Chenyan Hong, Yufan Wei, Ningning Min, Aiying Qi et al. · 2021 · Annals of Translational Medicine
92. Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study
    Pradeep S. Chauhan, Kevin Yi Chen, Ramandeep K. Babbra, Wenjia Feng, Nadja Pejovic, Armaan Nallicheri, Peter K. W. Harris, Katherine Dienstbach, Andrew Atkocius, Lenon Maguire et al. · 2021 · PLoS Medicine
93. DNA methylation-based classification of sinonasal tumors
    Philipp Sebastian Jurmeister, Stefanie Glöß, Renée F. Roller, Maximilian Leitheiser, Simone Schmid, Liliana H. Mochmann, Emma Payá Capilla, Rebecca Fritz, Carsten Dittmayer, Corinna Friedrich et al. · 2022 · Nature Communications
94. Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer
    Yoshie Kobayashi, Seung‐Oe Lim, Hirohito Yamaguchi · 2019 · Seminars in Cancer Biology
95. Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival
    Federica Miglietta, Michele Bottosso, Gaia Griguolo, Maria Vittoria Dieci, Valentina Guarneri · 2022 · ESMO Open
96. Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges
    Krisida Cerma, Federico Piacentini, Luca I. Moscetti, Monica Barbolini, Fabio Canino, Antonio Tornincasa, Federica Caggia, Sara Cerri, Alessia Molinaro, Massimo Dominici et al. · 2023 · Biomedicines
97. Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors
    Mariana Brandão, Rafael Caparica, Daniel Eiger, Evandro de Azambuja · 2019 · Annals of Oncology
98. PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases
    Petra Hillmann, Doriano Fabbro · 2019 · International Journal of Molecular Sciences
99. Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial
    Nicholas C. Turner, Rebecca Alexandra Dent, Joyce O’Shaughnessy, Sung‐Bae Kim, Steven Jay Isakoff, Carlos H. Barrios, Shigehira Saji, Igor Bondarenko, Zbigniew Ireneusz Nowecki, Qinshu Lian et al. · 2021 · Breast Cancer Research and Treatment
100. Trop-2 as a Therapeutic Target in Breast Cancer
     Elizabeth A. Sakach, Ruth Lauren Sacks, Kevin M. Kalinsky · 2022 · Cancers